Protocol Ledger

NCT06926205 · Phase II · RECRUITING

CHOP Plus Mosunetuzumab as First Line in Patients With Richter´s Syndrome: a Phase II Study of the Spanish Group of CLL

Interventional Phase II clinical trial protocol NCT06926205 sponsored by GELLC (Grupo Español de Leucemia Linfocítica Crónica) in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-05-15 Enrollment: 34 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06926205
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)34 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06926205
Protocol FieldVerified Registry Value
NCT IdentifierNCT06926205
Consolidated Lead SponsorGELLC (Grupo Español de Leucemia Linfocítica Crónica)
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment34 participants (ESTIMATED)
Registered Start Date2024-05-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI